3 results
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with prodromal or mild Alzheimer*s disease (AD), ages 50*80, who are amyloid positive by cerebrospinal fluid (CSF) or amyloid positron…
Target Population:Subjects with urinary incontinence (UI) caused by neurogenic detrusor overactivity (NDO)due to either spinal cord injury (SCI) or multiple sclerosis (MS), who have not beenadequately managed with oral medication and who routinely…
From protocol amendment 3 27JUn2022, Clinical Study Protocol Synopsis, page 1Primary Objective• To demonstrate superiority of fianlimab 1600 mg + cemiplimab and/or fianlimab 400 mg+ cemiplimab compared to pembrolizumab, as measured by progression-…